Sharemaestro Newsreel

Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates

Genelux Corporation announced its second-quarter 2026 financial results and provided business updates, including anticipated topline data from its Phase 3 OnPrime/GOG-3076 ovarian cancer trial in the second half of 2026. The company reported $18.7 million in cash, cash equivalents, marketable securities, and restricted cash …

Caris Life Sciences, Inc. - Common Stock (CAI) Stock Price, News, Quote & History

AQR group (VRXA) discloses 658,138-share Veraxa Biotech position under 5% threshold

AQR Capital Management, along with its affiliates, has reported a beneficial ownership of 658,138 Ordinary Shares in Veraxa Biotech Holding AG, which includes warrants. This position represents 0.46% of Veraxa’s outstanding Ordinary Shares, confirming that the AQR group holds less than the 5% threshold. …

Valion Bio (Nasdaq:VBIO) - analisi del titolo

This article provides an analysis of Valion Bio (Nasdaq: VBIO), an advanced-stage biopharmaceutical company with a market capitalization of US$546.7k. The company is developing Entolimod for Acute Radiation Syndrome (ARS) and oncology supportive care, facing significant risks including a highly volatile stock price, declining …

Replimune Group Stock Short Interest Rises to 57.95%

Replimune Group Inc. (NASDAQ:REPL) saw a significant increase in short interest during July, rising 57.95% to 5.25 million shares. This represents 14.7% of the company's shares outstanding, indicating a growing bearish sentiment among investors. The average daily trading volume suggests it would take approximately …

Stifel Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $318

Stifel has reiterated its Buy rating on Alnylam Pharmaceuticals (ALNY.US) and maintained its target price of $318. This indicates the firm's continued confidence in the company's stock performance.

Citizens cuts Spruce Biosciences stock price target on share dilution

Citizens has lowered its price target for Spruce Biosciences (NASDAQ: SPRB) from $150.00 to $144.00, citing potential share dilution indicated in the company's 10-Q filing, while maintaining a Market Outperform rating. Despite the reduction, the new target still suggests significant upside, though InvestingPro data …

Silence Therapeutics Locks In $175 Million to Fuel siRNA Pipeline After Upsized ADS Offering

Silence Therapeutics has secured $175 million in funding through an upsized public offering of American depositary shares (ADSs), exceeding its initial target of $150 million. This capital infusion follows positive Phase 2 results for its siRNA candidate, divesiran, in treating polycythemia vera, where it …

Pharvaris (NASDAQ:PHVS) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Kyntra Bio announced its second quarter 2026 financial results and provided a business update, highlighting significant progress in its oncology and rare disease pipeline. The company is on track for interim analysis of its Phase 2 trial for FG-3246 in mCRPC and aims to …

All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy

Mdxhealth Reports Second Quarter 2026 Financial Results

Mdxhealth reported a 16% increase in second-quarter 2026 revenue, reaching $27.2 million, driven by strong recovery in its tissue-based business and integration of ExoDx. The company reaffirmed its 2026 revenue guidance of $110-115 million and expects to return to positive adjusted EBITDA by the …

Sands Capital group (NASDAQ: IKT) discloses 9.3% Inhibikase stake plus large warrants

Sands Capital Life Sciences Pulse Fund II, L.P., along with related entities, has reported a beneficial ownership of 9.3% in Inhibikase Therapeutics, Inc. This stake includes 13,018,965 shares of common stock and substantial warrants for an additional 15.5 million shares, although these warrants are …

JPMorgan Chase & Co. Issues Pessimistic Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price

Nanobiotix S.A. (NBTX) investor group reports 9.4% stake and pre-funded warrants

An investor group led by Invus Public Equities, L.P. has reported a 9.4% beneficial ownership stake in Nanobiotix S.A. (NBTX), comprising 4,483,275 ordinary shares and 345,099 pre-funded warrants. The warrants are exercisable at Euro 0.03 per share and expire in May 2036. This filing, …

Kura Oncology, Inc. Stock 12‑Month Price Target Raised to $32, Implies 222% Upside

Analysts have raised the average 12-month price target for Kura Oncology, Inc. (KURA) stock from $31.17 to $32, with forecasts ranging from $15 to $76 per share. This new target suggests a potential upside of approximately 222% from its August 12 closing price. The …

H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $4

H.C. Wainwright has reiterated its Buy rating for Humacyte (HUMA.US), maintaining a price target of $4. This continued positive outlook from the analyst firm suggests confidence in the company's future performance.

Artelo Biosciences Releases Q2 2026 Financial Results

Artelo Biosciences, Inc. reported a net loss of $2.4M and a loss of $0.89 per share for Q2 2026, marking a significant improvement from the $16.8 per-share loss in Q2 2025. The clinical-stage biopharmaceutical company continues to advance its therapeutic pipeline targeting lipid-signaling pathways, …

Cabaletta Bio stock maintains Buy rating at TD Cowen on trial progress

TD Cowen has reiterated its Buy rating on Cabaletta Bio (NASDAQ:CABA) due to the company's progress in its RESET clinical trial portfolio. The stock has shown strong performance with a 30% year-to-date gain and 67% over the past year. Cabaletta Bio's pivotal trial data …

Achieve Life Sciences, Inc. Stock 12‑Month Price Target Cut to $13.83, Implies 107% Upside

Achieve Life Sciences, Inc.'s average 12-month price target has been lowered slightly from $13.91 to $13.83 by 12 analysts, with predictions ranging from $9 to $21 per share. This new target suggests a potential upside of approximately 107% from its closing price on August …

SRRK Maintains by JP Morgan -- Price Target Raised to $63.00

JP Morgan maintained an "Overweight" rating for Scholar Rock Holding Corp (SRRK) and raised its price target from $56.00 to $63.00, indicating a positive outlook. Despite this, the company has a low GF Score™ of 29/100 due to profitability and growth concerns, along with …

Korro Bio (NASDAQ:KRRO) Major Shareholder Acquires $19,283.78 in Stock

Lynx1 Capital Management, a major shareholder in Korro Bio (NASDAQ:KRRO), recently acquired 1,462 shares for $19,283.78, increasing its stake to 1.54 million shares. This follows another purchase of 5,222 shares earlier in the month. Korro Bio's stock rose 1.8% to $13.59, and the company …

Lynx1 Capital Management Lp Buys 5,222 Shares of Korro Bio (NASDAQ:KRRO) Stock

Lynx1 Capital Management Lp increased its stake in Korro Bio (NASDAQ:KRRO) by purchasing 5,222 shares for $59,530.80 and an additional 1,462 shares later. This brings their total holdings to 1.54 million shares. Korro Bio reported better-than-expected quarterly results with a loss of $1.07 per …

Sands Capital group (NASDAQ: ACRV) discloses 5.3% Acrivon ownership in 13G/A

Sands Capital Life Sciences Pulse Fund II, L.P. and its affiliated entities have disclosed a beneficial ownership of 5.3% in Acrivon Therapeutics, Inc. (NASDAQ: ACRV), totaling 2,289,271 shares. This information was reported in a Schedule 13G/A filing with the SEC, based on 42,853,362 shares …

ArriVent BioPharma Reports Second Quarter 2026 Financial Results

ArriVent BioPharma reported its second-quarter 2026 financial results, highlighting key advancements in its clinical pipeline. The company expects topline data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC in the second half of 2026, and its cash and investments of $373.1 million …

Agios Pharmaceuticals faces investigation after halting sickle cell drug development, stock drops 6.74%.

Agios Pharmaceuticals is under investigation by Pomerantz LLP for potential securities fraud after its stock fell 6.74%. This drop occurred following the company's announcement to cease development of tebapivat, a sickle cell disease drug, due to disappointing Phase 2 trial results. Investors affected by …

Assenagon Asset Management S.A. Has $3.86 Million Stock Holdings in Agios Pharmaceuticals, Inc. $AGIO

Assenagon Asset Management S.A. significantly increased its stake in Agios Pharmaceuticals, Inc. by 54.8% during the second quarter, bringing its total holdings to 103,955 shares valued at $3.86 million. This increase occurred despite Agios Pharmaceuticals reporting a slightly wider-than-expected quarterly loss of $1.69 per …

Artelo Plans Q4 Trial After ART26.12 Matches Naproxen for Pain

Artelo Biosciences reported its Q2 2026 financial results, with a narrowed net loss of $2.4 million and positive pipeline updates. The company plans a Phase 1 multiple ascending dose study for ART26.12 in Q4 2026, which has shown pain relief comparable to naproxen in …

CytomX Therapeutics (NASDAQ:CTMX) Given New $11.00 Price Target at JPMorgan Chase & Co.

JPMorgan Chase & Co. has lowered its price target for CytomX Therapeutics (NASDAQ:CTMX) from $12.00 to $11.00, while maintaining an "overweight" rating. This new target suggests a potential upside of 227.19% from the stock's previous close. The adjustment follows CytomX Therapeutics' recent quarterly report, …

AC Immune takes Parkinson's vaccine into US trials as Phase II data near

AC Immune SA's experimental alpha-synuclein vaccine, ACI-7104, has received US FDA clearance for its IND and Fast Track Designation for early-stage Parkinson's disease. This allows the vaccine to expand into US clinical development, as it approaches key Phase II data. Interim Phase II results …

Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says

RBC Capital Markets reiterated that Allogene Therapeutics remains an attractive investment due to its appealing valuation and distinctive clinical strategy. The company highlighted a 41% improvement in minimal residual disease on the large B-cell lymphoma front. Access to the full analysis requires a premium …

Scholar Rock (NASDAQ:SRRK) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

(URGN) Volatility Zones as Tactical Triggers

This article from Stock Traders Daily discusses Urogen Pharma Ltd. (NASDAQ: URGN) and presents AI-generated trading strategies based on volatility zones. It highlights strong sentiment across all time horizons supporting an overweight bias, notes the absence of resistance levels above the current price, and …

Alto Neuroscience (NYSE:ANRO) Trading 8% Higher Following Earnings Beat

Alto Neuroscience (NYSE:ANRO) shares rose 8% after reporting a quarterly loss of $0.65 per share, surpassing the consensus estimate of a $0.73 loss. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $36.62, and institutional investors like Commodore Capital and …

Abeona Therapeutics (ABEO) Stock Dips After Q2 Miss; Price-to-Sa

Ovid Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026